A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer

Phase 1/2 Completed 34 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a clinical study to observe the tolerance and primary efficacy of AL2846 capsules combined with Gemzar injection in patients with pancreatic cancer, and to determine the recommended dosage and administration method for subsequent clinical studies.

Timeline

Start: 2018-08-23
Primary completion: 2021-10-25
Completion: 2023-05-01

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper the MTD was not determined. PMID 39760815 ↗

Publications

Liu R, Ji Z, Wang X, Xin J, Zhu L, Ge S, Zhang L, Bai M, Ning T, Yang Y, Li H, Deng T, Ba Y. Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer. Invest New Drugs. 2025 Feb;43(1):81-92. doi: 10.1007/s10637-024-01485-5. Epub 2025 Jan 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AL2846	Small molecule	90 mg	—
Subject	AL2846	Small molecule	120 mg	—
Background	Gemcitabine	Small molecule	—	—